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Abstract 
DLC1 is a candidate tumor suppressor gene recently isolated from human hepatocellular 
carcinoma (HCC). Structurally, DLC1 protein contains a conserved RhoGAP domain, which 
has been thought to regulate the activity of Rho family proteins. Previous studies indicated that 
DLC1 was frequently inactivated in cancer cells. In the present study, we aimed to characterize 
the tumor suppressor roles of DLC1 in HCC. We demonstrated that DLC1 significantly 
inhibited cell proliferation, anchorage-independent growth and in vivo tumorigenicity when 
stably expressed in HCC cells. Moreover, DLC1 expression greatly reduced the motility and 
invasiveness of HCC cells. With RhoGAP deficient DLC1 mutant (DLC1-K714E), we 
demonstrated that the RhoGAP activity was essential for DLC1- mediated tumor suppressor 
function. Furthermore, the 292-648 a.a. region and START domain played an auxiliary role to 
RhoGAP and tumor suppressor function of DLC1. Taken together, our findings demonstrated 
that DLC1 functions as a tumor suppressor in HCC and provide the first evidence to support the 





Hepatocellular carcinoma (HCC) is the fifth commonest cancer worldwide and is the second 
leading fatal cancer in Southeast Asia and Hong Kong. Etiologically, HCC is closely 
associated with chronic hepatitis B and C virus infection, cirrhosis and aflatoxin B1 intake (1). 
However, the molecular mechanisms leading to the development and progression of HCC 
remain unclear. In HCC, deletions of chromosomal materials are common and of a non-random 
pattern, with recurrent deletions on chromosomes 1p, 4q, 8p, 13q, 16q and 17p. These strongly 
suggest that putative tumor suppressor genes may be located in these chromosome arms (2-7).  
 
Recently, a candidate tumor suppressor gene, namely frequently deleted in liver cancer (DLC1), 
was identified in primary HCC sample (8) and mapped to 8p21.3-22, where chromosomal 
deletion is particularly common in human cancers (2, 9-11). DLC1 mRNA encodes a protein 
with 1,091 amino acid residues and is ubiquitously expressed in human tissues (8). The amino 
acid sequence of DLC1 shares 86% homology with rat p122RhoGAP and this strongly 
suggests that DLC1 is a p122RhoGAP human ortholog. p122RhoGAP was first identified as a 
phospholipase C-δ1 binding protein in a rat brain expression library screening (12). 
Structurally, both p122RhoGAP and DLC1 contain three conserved functional domains, 
namely SAM (sterile alpha motif), RhoGAP (GTPase activating protein for Rho family protein) 
and START (steroidogenic acute regulatory related lipid transfer) domains (13, 14). Proteins 
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containing a RhoGAP domain usually function to catalyze the hydrolysis of GTP that is bound 
to Rho family proteins. When the bound GTP is hydrolyzed to GDP, Rho proteins return to the 
inactive basal state. Thus, RhoGAPs negatively regulate Rho-mediated cellular processes, such 
as actin cytoskeleton organization, gene expression, and cell-cycle progression (15, 16).  
 
Evidence has shown that hyperactivation of Rho proteins are oncogenic (17-20). Clinically, 
Rho proteins were found to be overexpressed in different human cancers and overexpression of 
Rho proteins was associated with more aggressive tumor behavior (21, 22). Several members 
of the RhoGAP family have been suggested to possess potential tumor suppressor function. For 
instance, anti-tumor function of p190RhoGAP has been demonstrated by in vitro studies. 
Overexpression of antisense p190RhoGAP RNA is able to transform normal NIH3T3 
fibroblasts. In contrast, overexpression of the wild-type p190RhoGAP domain can suppress 
v-Ha-Ras-induced transformation (23). Therefore, it is logical to hypothesize that DLC1 might 
have tumor suppressor functions by negatively regulating tumor cell growth or tumor 
progression through down-regulation of oncogenic activity of Rho family proteins.  
 
In this study, we demonstrated that DLC1 reduced the proliferation rate, anchorage- 
independent growth ability, and in vivo tumorigenicity of HCC cells. Stable expression of 
DLC1 also significantly suppressed the motility and invasiveness of HCC cells. Furthermore, 
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DLC1 inhibited Rho dependent stress-fiber formation in fibroblasts and HCC cells, and this 
Rho inhibitory function was essential for the DLC1- mediated growth inhibition in HCC cells. 
Thus, our findings support the hypothesis that DLC1 is a RhoGAP antagonizing the oncogenic 
activity of Rho proteins and serves as a tumor suppressor gene in human HCC.  
 
Materials and Methods 
Cell lines and plasmid construction 
Human HCC cell lines, SMMC-7721 and BEL7402, which lack DLC1 expression, were 
obtained from Shanghai Institute of Cell Biology (14, 24). The murine fibroblast cell line 
Swiss-3T3 was obtained form American Tissue Culture Collection (ATCC). The rodent 
fibroblast cell line Rat 6 was kindly provided by Dr. W.W. Hsiao (25). SMMC-7721 and 
BEL7402 were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 
10% (vol/vol) fetal bovine serum (FBS) and antibiotics. Swiss-3T3 and Rat 6 cells were 
cultured in DMEM supplemented with 10% (vol/vol) calf serum (CS) and antibiotics at 37˚C in 
a humidified incubator with 5% CO2.  
Plasmid construction  
A 3.5-kb fragment of full-length coding sequence of the DLC1 gene was amplified from 
normal liver tissue and cloned into pcDNA3.1(-) vector (26). Truncated fragments were 
subcloned into eukaryotic expression vector, pCS2+MT, of Myc-tagged protein as follows: 
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DLC1-FL (1-1091 a.a.), DLC1-SAM (1-292 a.a), DLC1-GAP (648-839 a.a), DLC1-START 
(879-1091 a.a), DLC1-N∆C (1-595 a.a.), DLC1-C∆N (648-1091 a.a), DLC1-∆ SAM (292-1091 
a.a) and DLC1-∆SAM∆START (292-839 a.a.). The DNA sequences and the reading frame of 
the recombinant plasmids were confirmed by DNA sequencing. 
Mutagenesis 
A DLC1 fragment (1-804 a.a) was released from pcDNA3.1/DLC1 plasmid by EcoRI digestion 
and subcloned into pBluescript II SK (+) vector. The site-specific mutation of K714E was 
introduced into DLC1 cDNA by PCR mutagenesis with two consecutive PCR amplifications. 
For the first PCR amplification, PCR fragments contain DLC1-K714E mutation was generated 
from pSK+/DLC1 (1-804 a.a.) with two set of PCR primers: 5’- GGA TGG ATG AGG AGA 
AGC TG -3’ (set 1, forward), 5’- GAT CTC GAA AAT ACT GCT CCA - 3’(set 1, reverse), 5’- 
TGC TGG AGC AGT ATT TTC GAG -3’ (set 2, forward) and 5’- TAA TAC GAC TCA CTA 
TAG GG -3’ (set 2, reverse). Subsequently, an aliquot of the first PCR products were used as 
templates for the second PCR, which was designed to amplify the full-length insert with the 
desired mutation in the DLC1 cDNA with the set 1 forward primer and set 2 reverse primer that 
have been used in the first PCR amplification. The final amplified product was excised and 
gel-purified. The NocI/BamHI fragment of DLC1 cDNA in pSK+/DLC1 (1-804 a.a) plasmid 
was then replaced by this PCR amplified fragment. The full length DLC1-K714E mutant was 
generated by releasing the DLC1-K714E fragment (1-804 a.a) from pSK+/DLC1 K714E 
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plasmids by EcoRI digestion and subcloned into pCS2+MT/DLC1 (805-1091 a.a.) plasmid, 
which was then verified by DNA sequencing.  
Establishment of DLC1 stably expressing cells 
Two µg of pcDNA3.1(-)/DLC1 plasmid was transfected into SMMC-7721 cells with FuGENE 
6 Transfection Reagent as described by the manufacturer (Roche Molecular Biochemicals, 
Indianapolis, IN). After 24 hours, the transfected cells were trypsinized and splitted onto 100 
mm culture dish at a density of 1 × 104/dish. Transfected cells were selected for 2 weeks in 
culture medium containing 0.75 mg/ml G418 (Invitrogen, Carlsbad, CA). Single 
G418-resistant clones were isolated from the culture dish using a Cloning cylinder (Bellco 
Biotechnology, Vineland, NJ). The expression of DLC1 was determined by RT-PCR and 
Northern blotting as described previously (14).  
Cell proliferation assay 
Cells (2.5 × 104) were plated in each well of 12-well culture plates containing 1 ml DMEM 
medium supplemented with 10% FBS or 0.5% FBS. Cells were harvested at 24-hour intervals 
for 7 days. Cell numbers were counted by trypan blue exclusion assay with hematocytometer. 
The doubling time of proliferating cells was determined by nonlinear regression (exponential 
growth) model using GraphPad Prism version 3.00 (GraphPad Software, San Diego CA)  
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Anchorage-independent growth assay in soft-agar 
Five ml of 0.5% agarose culture medium containing 10% FBS was used to coat the bottom of 
each of the wells of the 6-well culture plates. After hardening, 1 × 104 cells were suspended in 
2 ml of 0.3% agarose culture medium containing 10% FBS warmed at 40°C and plated onto the 
bottom layer. The cell solution was allowed to set for 30 minutes at room temperature before 
moving into the 37°C CO2 incubator. Colonies (≥10 cells) formed in the soft agarose culture 
were counted and photographed two weeks after inoculation. 
Cell motility assays 
For cell motility assay, 8 × 105 cells were seeded onto 60-mm dishes and grown for 24 hours. 
Cells were treated with 10 µg/ml mitomycin C (Sigma) for 3 hours prior to the wounding. A 
linear wound was made by scraping a pipette tip across the confluent cell monolayer. Cells 
were rinsed with phosphate buffered saline (PBS) and grown in DMEM supplemented with 
10% FBS for additional 48 hours. The cell motility in terms of wound closure was measured by 
photographing at 3 random fields at the time of wounding (time zero), 24 and 48 hours after 
wounding.  
In vitro cell invasion assay  
For in vitro cell invasion assay, 3 × 105 cells were suspended in 300 µl of serum-free DMEM 
medium and loaded onto the upper compartment of invasion chamber that contained a 
polycarbonate membrane with an 8 µm pore size and coated with a layer of extracellular matrix 
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(ECM) (Chemicon International, Temecula, CA). After 60 hours of incubation, the invasive 
cells which had migrated through the ECM layer to the complete medium in the lower 
compartment were stained, and the numbers of invasive cells were photographed and counted 
under the microscope. 
In vivo tumorigenicity assay 
SMMC-7721 and SMMC-7721/DLC1 cells were harvested and resuspended in PBS. One × 
106 cells were inoculated subcutaneously into the right flank of 6-week-old female BALB/C 
nude mice using a 25-gauge needle (5 mice for each group). Tumor size was monitored weekly 
by measure the largest and smallest diameters of tumor and estimated according to the formula: 
volume = 1/2 × (largest diameter) × (smallest diameter)2. This experiment was preformed 
following the Animals (Control of Experiments) Ordinance (H.K.) and Institute’s guidance on 
animal experiments. 
Immunofluorescence microscopy  
Five × 104 cells were seeded onto coverslips 16 hours prior to transfection. At 24 hours after 
transfection, cells were serum starved for an additional 24 hours and treated with 200 ng/ml 
lysophosphatidic acid (LPA) (Sigma) for 30 min. Cells were fixed in 4% paraformaldehyde in 
PBS and permeabilized with 0.2% Triton X-100 in PBS for 10 min. Fixed cells were blocked 
with 3% bovine serum albumin (BSA) and incubated with 1:1,000 rabbit polyclonal anti-Myc 
antibody (A14) (Santa Cruz, CA) for 2 hours followed by 1:100 FITC conjugated goat 
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anti-rabbit antibody (Amersham) and 1:1,000 rhodamine conjugated phalloidin (Sigma) for an 
hour with extensive washing in between. Cells were counterstained with 4,6 
diamidion-2-phenylindole (DAPI) (Calbiochem, San Diego, CA) and mounted in Vectashield 
antifade mountant (Vector Laboratory, Burlingame, CA). Images were captured under 
magnification of × 1,000 by a fluorescence microscope equipped with a charge-coupled device 
(CCD) camera (Leica, Wetzlar, Germany).  
Colony suppression assay 
Two × 105 cells were seeded onto 35 mm dish one day before transfection. Two µg each of the 
various pCS2+MT/DLC1 constructs or the pCS2+MT empty vector were co-transfected with 
0.2 µg pBABE-puro puromycin selection vector into the cells using FuGENE 6 Transfection 
Reagent (Roche Molecular Biochemicals). After 24 hours, cells were seeded onto 10 cm 
culture dishes in 1:5 dilution and grown in culture medium containing 0.6 µg/ml puromycin 
(Sigma) for 2 weeks. The puromycin-resistant colonies were fixed with 3.7% formaldehyde, 
and the colony formation efficiency was examined by Giemsa staining (Sigma).  
 
Results 
DLC1 inhibited cell proliferation, anchorage-independent growth and tumorigenicity of 
HCC cells 
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We have previously demonstrated that ectopic overexpression of DLC1 cDNA can suppress 
cancer cell growth in colony suppression assay (26). In order to further characterize the tumor 
suppressor function of DLC1 in HCC, in this study, we established a cellular model in which 
DLC1 cDNA was stably expressed in SMMC-7721 cells that lack endogenous DLC1 
expression. The ectopic expression of DLC1 in stably transfected cells was confirmed by 
semi-quantitative RT-PCR and Northern blot analysis (Figure 1A). To determine the effect of 
DLC1 on cell proliferation, we monitored the proliferation rate of DLC1 stably expressing 
SMMC-7721 cells (SMMC-7721/DLC1) for 7 days in a mitogen-dependent (10% FBS) and a 
mitogen-independent (0.5% FBS) manner. In both culture conditions, we observed that SMMC 
7721/DLC1 exhibited a significantly slower growing phenotype. The doubling time of 
SMMC-7721/DLC1 cells in mitogen-dependent and mitogen-independent conditions were, 
37.8 hrs (95% CI: 34.4 - 41.8 hrs) and 55.0 hrs (95% CI: 46.3-67.8 hrs), respectively. In 
contrast, the doubling time of parental SMMC-7721 cells were 29.5 hrs (95% CI: 27.5 - 31.8 
hrs) and 41.1 hrs (37.6-45.4 hrs), respectively (Figure 1B). These results indicated that DLC1 
exerts growth inhibitory effects on HCC cells. 
The capability of anchorage independent growth is an important indicator of malignant 
transformation. To substantiate the tumor suppression function of DLC1, we compared the 
anchorage-independent growth ability of SMMC-7721/DLC1 and SMMC-7721 cells in soft 
agar culture. As expected, the DLC1 stably transfected cells exhibited a dramatically reduced 
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ability to form colonies on soft agar. Both the number and size of colonies formed by DLC1 
stably expressing cells were significantly reduced as compared with those of the parental 
SMMC-7721 cells (P = 0.011, Figure 1C). Our findings suggest that ectopic expression of 
DLC1 is sufficient to suppress anchorage-independent growth in SMMC-7721 cells.  
Next, we determine the effects of DLC1 expression on the in vivo tumorigenicity in nude mice 
xenograft model. One x 106 cells were inoculated into the right flank of nude mice and the 
formation of solid tumor was monitored for 63 days. We observed that growth rate of DLC1 
expressing SMMC-7721 cells was significantly suppressed in nude mice (Figure 2). The above 
finding strongly suggests that DLC1 gene plays a tumor suppression role in human 
carcinogenesis. 
DLC1 suppressed cell motility and invasiveness of HCC cells 
To test whether DLC1 affects the motility of HCC cells, wound healing assay was performed 
on SMMC-7721 and SMMC-7721/DLC1 cells in the absence or presence of a cell division 
inhibitor, mitomycin C. Our results showed that the motility of DLC1 stably expressing cells 
was significantly reduced. Similar results were also obtained when the cells were pretreated 
with mitomycin C, which indicated that the reduction of cell motility in DLC1 expressing cells 
was not due to the difference in proliferation rate (Figure 3A). Consistently, the cell motility of 
SMMC-7721/DLC1 was significantly reduced in cell motility assay using invasion chamber 
without ECM coating, and this confirmed that expression of DLC1 inhibited cell motility 
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(Supplementary Figure 1). Furthermore, we asked whether DLC1 could suppress the 
invasiveness of HCC cells. To this end, we performed in vitro cell invasion assay using 
invasion chamber coated with an ECM layer (27). In sharp contrast with the parental 
SMMC-7721 cells, the number of invasive cells was dramatically reduced in DLC1 stably 
expressing cells (Figure 3B). Thus, our results clearly demonstrated that DLC1 suppressed the 
cell motility and invasiveness of HCC cells.   
Expression of DLC1 inhibited Rho-mediated stress fiber formation 
The existence of RhoGAP domain on DLC1 protein strongly suggests that DLC1 may function 
as a negative regulator toward the activity of Rho family proteins. Previously, we had 
demonstrated that bacterially expressed DLC1 protein significantly enhanced the intrinsic GTP 
hydrolysis activity of two well characterized Rho family proteins, RhoA and Cdc42 (14). This 
observation implied that DLC1 facilitated the conversion of the active GTP-bound Rho 
proteins to the GDP-bound inactive form. It is well known that Rho proteins play a critical role 
in regulating cytoskeleton organization and mediates actin stress-fiber formation upon 
extracellular stimulations (28, 29). Actin stress fibers are dissembled in serum starved cells but 
restored by LPA treatment through activation of Rho proteins. In this study, we further tested 
the in vivo RhoGAP activity of DLC1 by transiently expressing myc-tagged DLC1 cDNA in 
HCC cell lines and fibroblast cell lines. The effects of DLC1 on the activity of Rho proteins 
were examined under fluorescence microscope with regard to morphological changes and actin 
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stress fiber formation. As shown in Figure 4B, LPA induced the formation of actin stress fibers 
in serum starved SMMC-7721 cells. However, in DLC1 overexpressing cells, the formation of 
actin stress fibers was significantly suppressed. Furthermore, overexpression of DLC1 resulted 
in extensive cell rounding and cortical retraction. It is of note that these morphological changes 
were remarkably similar to that caused by the Rho inhibitor, C3 exoenzyme, in HeLa cells (30) 
suggesting that these morphological changes were due to inhibition of Rho proteins. Consistent 
observation was obtained form both HCC cell lines SMMC-7721 and BEL7402 as well as 
fibroblast cell lines Swiss-3T3 and Rat6 suggesting that the effects of DLC1 on actin-stress 
fiber formation and cell morphological changes were not cell line specific response.  
In silico analysis had revealed that several lysine and arginine residues are highly conserved in 
various mammalian RhoGAPs. A previous study on the rat p122RhoGAP (DLC1 ortholog) has 
provided evidence that Lys-706 residue is involved in stimulating the GTP hydrolysis of active 
GTP-bound Rho proteins (13). To further confirm the RhoGAP function of DLC1, we 
constructed a RhoGAP deficient mutant by converting the Lys-714 into glutamate (K714E), 
which corresponds to the Lys-706 in rat p122RhoGAP. Expression of DLC1-K714E mutant 
abolished the DLC1 induced cell rounding and cortical retraction. In addition, upon LPA 
induction, DLC1-K714E mutant expressing cells formed actin stress fibers as efficiently as the 
empty vector control (Figure 4B). Similar findings were also reproduced in another DLC1 null 
HCC cell line (BEL7402) as well as in fibroblast cell lines (Swiss-3T3 and Rat 6) (data not 
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shown). Taken together, our results strongly suggest that DLC1 functions as a RhoGAP and 
negatively regulates the activity of Rho proteins in vivo. 
RhoGAP activity was essential for DLC1 mediated tumor suppressor function 
We hypothesized that DLC1 suppressed cancer cell growth through negatively regulating the 
activity of Rho proteins. In order to test this hypothesis, colony suppression assays were 
performed on SMMC-7721 cells transfected with wild-type and RhoGAP deficient mutant 
DLC1. We found that ectopic overexpression of wild-type DLC1 significantly suppressed the 
colony formation in HCC cells (Figure 5A). Indeed, this finding was highly consistent with that 
found in cancer cell lines of different tissue types as reported by us and others (26, 31, 32). In 
contrast to wild-type DLC1, expression of the RhoGAP-deficient mutant had no effect on the 
colony formation ability of SMMC-7721 cells. The number of colony formed by DLC1-K714E 
transfected cells was comparable to that of the empty vector (Figure 5A). Thus, our data 
suggest that the RhoGAP activity is essential for DLC1 mediated tumor suppressor function 
and lend further support to the notion that DLC1 exerts tumor suppressor function by 
negatively regulating the activity of Rho proteins. 
Cooperation among the multi-functional domains of DLC1 was required for its growth 
inhibition of HCC cells 
DLC1 contains three conserved functional domains. Apart from the RhoGAP domain, SAM 
and START domains are located at the N-terminal and C-terminal of the DLC1 protein, 
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respectively (Figure 4A). We have demonstrated in this study that the RhoGAP domain of 
DLC1 is essential for negative regulation of Rho activity and suppression of cancer cell growth. 
However, the roles of the SAM and START domains in DLC1 functions are largely unclear. 
To address this question, we expressed different truncated DLC1 cDNAs in SMMC-7721 cells 
(Figure 4A). The expression of the truncated DLC1 proteins was confirmed by western blotting 
using anti-Myc antibody (Figure 5B). The RhoGAP activity and tumor suppressor function of 
these truncated constructs were determined by their ability to inhibit Rho mediated actin stress 
fiber formation (Figure 4B) and to suppress colony formation (Figure 5A) in HCC cells, 
respectively. Since RhoGAP is essential for DLC1-mediated tumor suppressor function, we 
first asked whether the RhoGAP domain alone was sufficient to inhibit the activity of Rho 
proteins and suppress colony formation in HCC cells as efficiently as the wild-type DLC1. In 
this regard, we transiently expressed the DLC1 fragment containing the RhoGAP domain 
(DLC1-GAP) in SMMC-7721 cells. Surprisingly, the DLC1-GAP failed to induce 
morphological change and inhibit actin stress fiber formation when overexpressed in HCC 
cells (Figure 4B). Moreover, we did not find any significant difference in the colony formation 
ability between HCC cells expressing DLC1-GAP and those transfected with empty vector 
alone (Figure 5A). Similarly, the colony formation ability of HCC cells expressing DLC1 
fragment containing either the SAM domain (DLC1-SAM) or START domain (DLC1-START) 
alone was also comparable to that of the empty vector control (Figure 5A). DLC1-SAM and 
 17
DLC1-START also had no effect on HCC cell morphology as well as stress fiber formation 
(data not shown). These observations suggest that SAM, RhoGAP or START domain on their 
own is insufficient to inhibit the activity of Rho proteins or suppress colony formation in HCC 
cells. Thus, cooperation among multi-functional domains in DLC1 is required for RhoGAP and 
tumor suppressor functions.   
Next we tested the RhoGAP and tumor suppressor functions of C-terminal (DLC1-C∆N) and 
SAM domain-deleted (DLC1-∆SAM) fragments of DLC1 in SMMC-7721 cells. C-terminal of 
DLC1 showed no suppressive effects on the stress fibers and colony formation, while 
expression of DLC1-∆SAM resulted in extensive cell rounding and cortical retraction 
accompanied with loss of actin stress fiber formation (Figure 4B). In addition, DLC1-∆SAM 
also significantly suppressed colony formation in HCC cells (Figure 5A). These findings 
indicate that SAM domain is not necessary for the RhoGAP and tumor suppressor function of 
DLC1 while an unidentified functional domain located between SAM and RhoGAP (i.e. amino 
acid residues 292-639) may play an important role in regulating DLC1 functions. To test the 
role of START domain in DLC1-mediated functions, we further expressed the N-terminal 
(DLC1-N∆C) and the SAM and START domain-deleted fragment (DLC1-∆SAM∆START), 
respectively, in HCC cells. Like the C-terminal fragment, expression of the N-terminal 
fragment of DLC1 also had no effects on the cell morphology and colony formation efficiency 
of HCC cells. However, compared with DLC1-∆SAM, further deletion of the START domain 
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resulted in loss of the inhibitory effect on actin stress fiber formation and colony formation in 
HCC cells (Figure 4B & 5A). These findings indicate that the START domain is indispensable 
for DLC1-mediated RhoGAP and growth inhibitory function. The concurrence of RhoGAP 
domain and growth inhibitory functions among these various truncated DLC1 constructs 
provides further evidence to support the notion that the RhoGAP activity is essential for DLC1 
mediated tumor suppression (Figure 4A). Similar results were also obtained when these 
experiments were performed in BEL7402 and Rat 6 cell lines, indicating that these findings 
were not merely due to a cell line specific phenotype (data not shown).  
 
Discussion 
DLC1 is a candidate tumor suppressor gene recently isolated from PCR-based subtractive 
hybridization in human HCC (8). Follow-up studies indicate that inactivation of DLC1 is 
implicated in hepatocarcinogenesis (14, 26, 33, 34). Although somatic mutations in DLC1 gene 
are rare (14, 35, 36), loss of heterozygosity is present in approximately half of primary HCCs 
(8, 14, 35). DLC1 mRNA expression is significantly down-regulated in primary HCC samples 
(14, 26). Earlier in vitro studies using hepatoma cell lines not expressing DLC1 have revealed 
that epigenetic alterations, including promoter methylation, are also responsible for DLC1 
silencing in HCC (14, 34). In addition, methylation of the DLC1 promoter was detected in 
about 24% of primary HCC samples (14). These findings suggest that epigenetic silencing of 
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DLC1 is not merely an artifact introduced by in vitro tissue culture but may substantially 
contribute to human carcinogenesis (14). The frequent inactivation of the DLC1 gene in HCC 
prompted us to further investigate its tumor suppressor functions. We previously showed that 
transfection of DLC1 cDNA into HCC cell lines resulted in inhibition of colony formation (26). 
Recently, inactivation of the DLC1 gene has also been observed in human breast, gastric and 
lung cancers (31, 32, 37, 38), suggesting that DLC1 functions as a bona fide tumor suppressor 
gene. Although several lines of evidence support the tumor suppression role of DLC1, little is 
known about the functions of the DLC1 and how it is implicated in human carcinogenesis.  
To further substantiate the tumor suppressor function of DLC1, we stably expressed DLC1 
cDNA in SMMC-7721 cells. Expression of DLC1 cDNA significantly suppressed cell 
proliferation in both mitogen-dependent and mitogen-independent cultures. In addition, stable 
expression of DLC1 resulted in reduction of anchorage-independent growth capability. DLC1 
expression also suppressed the tumorigenicity of SMMC-7721 cells in nude mice xenograft 
model. Consistent with our findings, Yuan et al. recently demonstrated that introduction of the 
DLC1 cDNA into other cancer cell lines also abolished the in vivo tumorigenicity in nude mice 
(32, 33). The above findings, when taken together, strongly suggest the DLC1 gene functions 
as a tumor suppressor in human carcinogenesis. 
Our previous in vitro study indicated that DLC1 negatively regulated the activity of Rho family 
proteins by promoting the GTP hydrolysis (14). In the present study, we further demonstrated 
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that DLC1 expression could significantly suppress Rho-dependent actin stress fibers formation 
in HCC and fibroblast cell lines. Thus, our findings strongly imply that overexpression of 
DLC1 can inhibit the activity of Rho proteins and further support the notion that DLC1 
functions as RhoGAP in vivo. 
Cell motility is tightly regulated by the activity of Rho proteins through actin cytoskeletal 
rearrangements (29). Recently, a growing body of evidence has suggested that deregulation of 
Rho proteins are implicated in cancer cell invasion and metastasis. For instance, 
overexpression of wild-type RhoA in rat hepatoma cells induced cell invasion in both in vitro 
and in vivo conditions (39). On the other hand, dominant negative RhoA (RhoA N19) was 
sufficient to inhibit the invasiveness of human prostate cancer cells (40). It has also been 
documented that RhoA specific inhibitor C3 exoenzyme greatly suppressed the cell motility of 
HCC cell lines, Li7 and KYN-2. In sharp contrast, the cell motility of these cell lines was 
strongly induced by LPA treatment (41). Based on the above evidence, we hypothesize that 
DLC1, a negative regulator of Rho proteins, will reduce cell motility. Indeed, our data clearly 
showed that expression of DLC1 significantly inhibited cell motility and invasiveness of HCC 
cells.  
More than 30 potential down-stream effectors of Rho family proteins have been identified (42). 
These effectors may be responsible for the different specific cellular functions mediated by the 
Rho proteins. ROCK is one of the best characterized down-stream effectors which selectively 
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binds to active GTP bound Rho proteins and regulates cell cytoskeletal reorganization through 
phosphorylating a wide range of cytoskeletal proteins (43, 44). Recent studies indicated that 
deregulation of Rho/ROCK signaling pathway is responsible for cancer invasion and 
metastasis (22, 41, 45). It is tempting to speculate that DLC1 suppresses cell motility and 
invasiveness through down-regulation of the Rho/ROCK signaling pathway. Further 
experiments are warrant to clarify the functional relationship between DLC1 and Rho/ROCK 
signaling pathway. 
To further characterize the Rho inhibitory and tumour suppressor activity of DLC1, various 
DLC1 truncated mutants was generated. RhoGAP deficient mutant abolished DLC1 mediated 
growth inhibition when expressed in HCC cells. Thus, our results have demonstrated for the 
first time that the RhoGAP activity of DLC1 is essential for its tumor suppressor function. 
Surprisingly, ectopic expression of the DLC1 RhoGAP domain alone did not inhibit stress fiber 
and colony formation. These observations indicate that, apart from the RhoGAP domain, other 
functional domains of the DLC1 protein may also play some cooperative role in regulating the 
DLC1 function in vivo. Indeed, deletion of START domain of DLC1 resulted in impaired 
inhibition on actin stress fiber and colony formation, suggesting that the START domain may 
play an auxiliary role to DLC1 in inhibiting Rho activity and tumor cell growth. The exact 
function of START domain is largely unknown, but a previous study on the other START 
domain-containing proteins indicated that this domain might be involved in membrane 
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targeting and lipid-binding (46). We speculate that START domain in DLC1 may be 
responsible for targeting DLC1 to particular subcellular localization where its specific 
substrates locate. We also noticed that the expression of C-terminal of DLC (648-1091 a.a), 
which contains intact RhoGAP and START domain, did not affect the actin stress fiber 
formation and was unable to suppress colony formation in HCC cells. However, DLC1-∆SAM 
(292-1091 a.a.) significantly inhibited the activity of Rho proteins and colony formation ability 
of HCC cells. This result strongly suggests that an unidentified functional domain located at 
292-638 may be important for the DLC1 mediated RhoGAP and tumor suppressor functions. 
Thus, we propose that both the RhoGAP and START domains and an unidentified domain 
located within the region of 292-638 amino acid residues are required for DLC1-mediated 
growth and stress fiber inhibition, and further investigations are warranted in this regard. 
Furthermore, similar with the RhoGAP deficient mutant, we noticed a close association 
between RhoGAP activity and tumor suppressor function of various truncated DLC1 cDNAs. 
Thus our results suggest that DLC1 tumor suppressor function are related to its Rho protein 
inhibitory activity. 
In conclusion, our findings thus far have indicated that DLC1 significantly inhibited 
Rho-mediated actin stress fiber formation, and the RhoGAP activity of DLC1 was essential for 
tumor suppressor function. Expression of DLC1 suppressed cell proliferation, 
anchorage-independent growth, tumorigenicity and invasiveness of HCC cells. 
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Legend for figures  
Figure 1. Stable expression of DLC1 inhibited cell proliferation and 
anchorage-independent growth. (A) Stably expression of DLC1 in SMMC-7721, left panel: 
RT-PCR, right panel: Northern blotting. (B) DLC1 inhibited cell proliferation in SMMC-7721. 
Cells were harvested and counted at 24-hr intervals for 7 days. Data represent the mean and 
S.D of three independent experiments. (C) DLC1 expression suppressed 
anchorage-independent growth of HCC cells (P = 0.011, t-test). Cells were grown in soft agar 
culture for 2 weeks and the efficiency of colony growth was examined under the microscope. 
The data represent the mean and SD of three independent experiments. 
Figure 2. DLC1 suppressed tumorigenicity in nude mice. One × 106 cells were inoculated 
subcutaneously into the right flank of 6-week-old female BALB/C nude mice (5 mice for each 
group). Tumor size was estimated according to the formula: volume = 1/2 × (largest diameter) 
× (smallest diameter)2.  
Figure 3. DLC1 inhibited cell motility and invasiveness in HCC. (A) The ability of 
SMMC-7721 and SMMC-7721/DLC1 grown in a confluent monolayer to migrate into a linear 
wound created by a pipette tip in the absence (left) or presence (right) of the cell division 
inhibitor, mitomycin C (10 µg/ml), was monitored for 48 hrs. (B) The invasiveness of the HCC 
cells was assayed with ECM-coated invasion chamber. Invasive cells were stained, 
photographed and counted under the microscope. The data represent the mean and S.D of three 
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independent experiments. Expression of DLC1 significantly inhibited cell invasion of 
SMMC-7721 (P < 0.001, t-test).   
 
Figure 4. The effect of DLC1 on cell morphology and Rho-dependent stress-fiber 
formation (A) Schematic representation of the various constructs of DLC1. The full-length 
DLC1, DLC1-FL (1-1091), contains three major functional domains, namely SAM, RhoGAP, 
and START. Various fragments of DLC1 cDNA were subcloned into Myc-tagged expression 
vector, pCS2+MT. +: significant inhibition of actin-stress fiber formation or colony formation 
in HCC cells; -: no significant inhibition of actin-stress fiber formation or colony formation in 
HCC cells. (B) The morphological change and actin stress fiber formation of SMMC-7721 
cells transfected with various DLC1 mutants. SMMC-7721 cells grown on glass cover slips 
were transfected with Myc-tagged DLC1 mutants or empty vector. Cells were serum starved 
for 18 hr and the formation of stress-fibers was induced by LPA. The expression of DLC1 was 
determined by polyclonal anti-myc antibody (A14) followed by FITC-conjugated goat 
anti-rabbit antibody. The actin stress fibers were stained with rhodamine conjugated phalloidin. 
Arrow heads: Cells expression of DLC1-FL and DLC1-∆SAM significantly inhibited stress 




Figure 5. Tumor suppressor function of DLC1 mutants (A) Colony suppression assays of 
SMMC-7721 cells transfected with DLC1 mutants. The data represent the mean and S.D of 
three independent experiments. Similar findings were also obtained from another HCC cell line 
BEL7402 lacking endogenous DLC1 expression (data not shown). (B) Expression of DLC1 
mutants in SMMC-7721 cells. DLC1 expression were detected by Western blotting and 
confirmed that all DLC1 mutants were at expected size and were expressed at similar level. NS: 
non-specific bands. 
 
Supplementary Figure 1. Stably expression of DLC1 inhibited cell motility. Cell motility 
of SMMC-7721 and SMMC-7721/DLC1 were examined by in-vitro cell motility assay using 
invasion chamber without ECM coating. 0.4 × 105 cells were suspended in 300 µl of serum-free 
DMEM medium and loaded onto the upper compartment of invasion chamber that contained a 
polycarbonate membrane with an 8 µm pore size. After 16 hours of incubation, the invasive 
cells which had migrated through the membrane to the complete medium in the lower 
compartment were stained, and the numbers of invasive cells were photographed and counted 
under the microscope. The data represent the mean and S.D of three independent experiments. 
Expression of DLC1 significantly inhibited cell motility of SMMC-7721 (P < 0.001, t-test).   






